May 28, 2026 · Boulder BioLabs

FDA's 2025 Endotoxin Testing Guidance: What It Says, What It Means, and What's Actually New

Current FDA endotoxin guidance status, where it's moving on rFC and CSF-contact limits, and what to do now.

FDA's Pyrogen and Endotoxins Testing guidance was last revised in 2015, and the agency has been signaling an update — particularly around recombinant Factor C (rFC) methods and CSF-contact thresholds. Here's a working summary of where the guidance currently stands, what's likely to change, and what's worth doing now.

Current State (2015 Guidance, Still Active)

• Blood-contact limit: 0.5 EU/mL or 20 EU/device, K/M-based calculation
• CSF-contact limit: 2.15 EU/device (the most stringent commonly-encountered limit)
• Method approval: LAL (gel-clot, turbidimetric, chromogenic) with inhibition/enhancement validation
• rFC method: acknowledged but with caveats around regulatory acceptance

Where It's Moving

• Increased FDA receptiveness to rFC for environmental sustainability reasons (horseshoe crab population concerns)
• Tighter expectations around inhibition/enhancement re-validation cadence
• Increasing FDA scrutiny on combination devices and CSF-contacting neurostimulators

What to Do Now

1. If your device is CSF-contacting, verify your current EU/device limit is 2.15 or lower in your QMS document.
2. Confirm your inhibition/enhancement study is current — many programs treat I/E as a one-time event, but FDA expects re-qualification on material changes.
3. If you're considering rFC, talk to your contract lab about validation pathway before switching.

How Boulder BioLabs Helps

LAL/BET testing with gel-clot, kinetic turbidimetric, and kinetic chromogenic methods. Co-located release path: sterility, endotoxin, and residuals returns from one sample drop.